{
    "Trade/Device Name(s)": [
        "APTIMA Combo 2 Assay",
        "APTIMA Combo 2 Assay on the PANTHER System"
    ],
    "Submitter Information": "Gen-Probe Incorporated",
    "510(k) Number": "K111409",
    "Predicate Device Reference 510(k) Number(s)": [
        "K032194"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LSL",
        "MKZ",
        "NSU"
    ],
    "Summary Letter Date": "April 20, 2012",
    "Summary Letter Received Date": "April 23, 2012",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3120",
        "21 CFR 866.3390"
    ],
    "Regulation Name(s)": [
        "DNA Probe",
        "DNA Reagents, Neisseria",
        "Nucleic Acid Amplification, Chlamydia"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "virology"
    ],
    "Analyte(s)": [
        "Chlamydia trachomatis rRNA",
        "Neisseria gonorrhoeae rRNA"
    ],
    "Specimen Type(s)": [
        "Clinician-collected endocervical swab",
        "Clinician-collected vaginal swab",
        "Patient-collected vaginal swab",
        "Male urethral swab",
        "Gynecological specimen collected in PreservCyt Solution"
    ],
    "Specimen Container(s)": [
        "APTIMA specimen transport tube",
        "PreservCyt Solution collection device"
    ],
    "Instrument(s)/Platform(s)": [
        "PANTHER System"
    ],
    "Method(s)/Technology(ies)": [
        "Target capture",
        "Transcription-Mediated Amplification (TMA)",
        "Hybridization Protection Assay (HPA)",
        "Nucleic acid amplification"
    ],
    "Methodologies": [
        "Nucleic acid probe test",
        "RNA target amplification",
        "Qualitative detection and differentiation"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "System",
        "Specimen collection device"
    ],
    "Document Summary": "FDA 510(k) summary for APTIMA Combo 2 Assay on the PANTHER System for automated qualitative detection of Chlamydia trachomatis and Neisseria gonorrhoeae rRNA",
    "Indications for Use Summary": "For in vitro qualitative detection and differentiation of ribosomal RNA from Chlamydia trachomatis and/or Neisseria gonorrhoeae to aid in diagnosis of urogenital disease using the PANTHER System, with various swab and gynecological specimens from symptomatic and asymptomatic individuals",
    "fda_folder": "Microbiology"
}